Compounds > metformin

metformin and pf 04971729

metformin has been researched along with pf 04971729 in 20 studies

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's12 (60.00)24.3611
2020's8 (40.00)2.80

Authors

AuthorsStudies
Amin, NB; Jain, SM; Lee, DS; Nucci, G; Rusnak, JM; Wang, X1
Charbonnel, B; Darekar, A; Frias, J; Huyck, S; Lauring, B; Páll, D; Pascu, R; Rosenstock, J; Saur, D; Shi, H; Terra, SG1
Amorin, G; Dagogo-Jack, S; Eldor, R; Engel, SS; Golm, G; Hille, D; Huyck, S; Johnson, J; Lauring, B; Liao, Y; Liu, J; Mancuso, JP; Terra, SG1
Eldor, R; Engel, SS; Golm, G; Huyck, SB; Johnson, J; Lauring, B; Mancuso, JP; Pratley, RE; Qiu, Y; Raji, A; Sunga, S; Terra, SG1
Markham, A1
Alvey, C; Cutler, DL; Dawra, VK; Hickman, A; Krishna, R; Liang, Y; Sahasrabudhe, V; Saur, D; Shi, H; Terra, SG; Zhou, S1
Bass, A; Dawra, VK; Fediuk, DJ; Hickman, A; Krishna, R; Liang, Y; Matschke, K; Sahasrabudhe, V; Shi, H; Terra, SG; Zhou, S1
Charbonnel, B; Darekar, A; Gallo, S; Goldman, A; Huyck, S; Lauring, B; Shi, H; Terra, SG1
Frias, JP1
Bass, A; Cutler, D; Dawra, VK; Hickman, A; Liang, Y; Sahasrabudhe, V; Shi, H; Terra, SG; Zhou, S1
Huyck, S; Ji, L; Lauring, B; Liu, S; Liu, Y; Miao, H; Mu, Y; Pan, S; Qiu, Y; Terra, SG; Wang, W; Xie, Y; Yan, P; Yang, M1
Kuhad, A; Razdan, K; Sharma, R1
Bass, A; Dawra, VK; Hickman, A; Krishna, R; Liang, Y; Pelletier, K; Sahasrabudhe, V; Shi, H; Terra, SG; Wei, H; Zhou, S1
Scheen, AJ1
Dawra, VK; Hickman, A; Krishna, R; Matschke, K; Pelletier, K; Sahasrabudhe, V; Shi, H; Zhou, S1
Gallo, S; Gantz, I; Greenberg, M; Lingvay, I; Liu, J; Shi, H1
Athyros, VG; Boutari, C; Karagiannis, A1
Cannon, CP; Cherney, DZI; Cosentino, F; Dagogo-Jack, S; Frederich, R; Gantz, I; Liu, J; Mancuso, JP; Pong, A; Pratley, RE1
Cannon, CP; Cater, NB; Cherney, DZI; Cosentino, F; Dagogo-Jack, S; Frederich, R; Maldonado, M; Mancuso, JP; McGuire, DK; Pratley, RE; Wang, S1
Cannon, CP; Cherney, DZI; Cosentino, F; Dagogo-Jack, S; Frederich, R; Gantz, I; Liu, J; Masiukiewicz, U; Pratley, RE; Shi, H1

Reviews

3 review(s) available for metformin and pf 04971729

ArticleYear
Ertugliflozin: First Global Approval.
    Drugs, 2018, Volume: 78, Issue:4

    Topics: Blood Glucose; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; United States; United States Food and Drug Administration

2018
Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes.
    Expert review of endocrinology & metabolism, 2019, Volume: 14, Issue:2

    Topics: Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Treatment Outcome

2019
Ertugliflozin for the treatment of type 2 diabetes.
    Drugs of today (Barcelona, Spain : 1998), 2019, Volume: 55, Issue:3

    Topics: Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2019

Trials

14 trial(s) available for metformin and pf 04971729

ArticleYear
Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:6

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Genital Diseases, Female; Genital Diseases, Male; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Mycoses; Sitagliptin Phosphate; Sodium-Glucose Transport Proteins; Urinary Tract Infections

2015
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).
    Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:3

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Bone Density; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss; Young Adult

2018
Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.
    Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:3

    Topics: Blood Pressure; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2018
Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
    Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:5

    Topics: Aged; Body Mass Index; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Overweight; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors

2018
Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects.
    Clinical pharmacology in drug development, 2019, Volume: 8, Issue:3

    Topics: Adolescent; Adult; Bridged Bicyclo Compounds, Heterocyclic; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Female; Glucuronosyltransferase; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Sulfonylurea Compounds; UDP-Glucuronosyltransferase 1A9; Young Adult

2019
Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed-Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin.
    Clinical pharmacology in drug development, 2019, Volume: 8, Issue:5

    Topics: Adult; Bridged Bicyclo Compounds, Heterocyclic; Cross-Over Studies; Dietary Fats; Drug Combinations; Female; Food-Drug Interactions; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Young Adult

2019
Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.
    Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:4

    Topics: Aged; Blood Glucose; Bone Density; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Mycoses; Reproductive Tract Infections; Sulfonylurea Compounds; Vulvovaginitis

2019
A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects
.
    International journal of clinical pharmacology and therapeutics, 2019, Volume: 57, Issue:4

    Topics: Adolescent; Adult; Bridged Bicyclo Compounds, Heterocyclic; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Healthy Volunteers; Humans; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Young Adult

2019
Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia.
    Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:6

    Topics: Aged; Asia, Eastern; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Metformin; Middle Aged; Philippines; Sodium-Glucose Transporter 2 Inhibitors

2019
Bioequivalence of Ertugliflozin/Metformin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components.
    Clinical pharmacology in drug development, 2020, Volume: 9, Issue:1

    Topics: Adolescent; Adult; Bridged Bicyclo Compounds, Heterocyclic; Cross-Over Studies; Drug Combinations; Fasting; Female; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Tablets; Therapeutic Equivalency; Young Adult

2020
Bioequivalence of Metformin in Ertugliflozin/Metformin Fixed-Dose Combination Tablets to Canadian-Sourced Metformin Coadministered With Ertugliflozin Under Fasted and Fed States.
    Clinical pharmacology in drug development, 2021, Volume: 10, Issue:5

    Topics: Adult; Area Under Curve; Bridged Bicyclo Compounds, Heterocyclic; Canada; Cross-Over Studies; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Tablets; Therapeutic Equivalency; Young Adult

2021
Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy.
    Diabetes, obesity & metabolism, 2021, Volume: 23, Issue:7

    Topics: Blood Glucose; Bridged Bicyclo Compounds, Heterocyclic; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2021
Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial.
    Circulation, 2022, 08-23, Volume: 146, Issue:8

    Topics: Bridged Bicyclo Compounds, Heterocyclic; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors

2022
Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV.
    The Journal of clinical endocrinology and metabolism, 2023, Jul-14, Volume: 108, Issue:8

    Topics: Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Metformin; Sodium-Glucose Transporter 2 Inhibitors

2023

Other Studies

3 other study(ies) available for metformin and pf 04971729

ArticleYear
[Ertugliflozin alone and in fixed-dose combinations : «pass of three»].
    Revue medicale de Liege, 2020, Volume: 75, Issue:9

    Topics: Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin

2020
Ertugliflozin + metformin as a treatment option for type 2 diabetes.
    Expert opinion on pharmacotherapy, 2021, Volume: 22, Issue:16

    Topics: Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors

2021
Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV.
    Diabetes, obesity & metabolism, 2022, Volume: 24, Issue:7

    Topics: Bridged Bicyclo Compounds, Heterocyclic; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucose; Humans; Hypoglycemic Agents; Insulin; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2022